3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
47
Melanoma
23
Neoplasm Metastasis
19
Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
17
Lung Neoplasms
13
Skin Neoplasms
12
Recurrence
10
Head and Neck Neoplasms
10
Carcinoma, Renal Cell
9
Prostatic Neoplasms
8
Ovarian Neoplasms
8
Colorectal Neoplasms
8
Carcinoma, Squamous Cell
8
Breast Neoplasms
8
Urinary Bladder Neoplasms
7
Carcinoma, Merkel Cell
7
Triple Negative Breast Neoplasms
6
Colonic Neoplasms
6
Carcinoma, Basal Cell
6
Carcinoma
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Sarcoma
5
Pancreatic Neoplasms
5
Glioblastoma
5
Stomach Neoplasms
4
Multiple Myeloma
4
Mouth Neoplasms
4
Fallopian Tube Neoplasms
4
Interventions
Pemetrexed
9
Nivolumab
8
Cisplatin
8
Carboplatin
8
pembrolizumab
7
130-nm albumin-bound paclitaxel
7
Gemcitabine
6
padeliporfin
5
durvalumab
5
Paclitaxel
5
Bevacizumab
5
palbociclib
4
napabucasin
4
atezolizumab
4
Irinotecan
4
Fulvestrant
4
Fluorouracil
4
Cyclophosphamide
4
ribociclib
3
osimertinib
3
cobimetinib
3
alectinib
3
abemaciclib
3
Trastuzumab
3
Sunitinib
3
Radiosurgery
3
Drug Therapy
3
Docetaxel
3
Cetuximab
3
Anastrozole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms by Site
×
cemiplimab
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled